Targeting inhibitory immune checkpoint molecules has dramatically changed treatment
paradigms in medical oncology. Understanding the best strategies to unleash a pre-existing …

Background T-cell immunoglobulin mucin-1 (TIM-1) has been reported to be associated with
the biological behavior of several malignant tumors; however, it is not clear whether it has a …

The T‑cell immunoglobulin and mucin domain‑containing protein 3 (Tim‑3)/galectin 9 (Gal‑9)
pathway, which serves a pivotal role in immune regulation, is similar to the programmed …

Immune checkpoint blockade has shown unprecedented and durable clinical response in a
wide range of cancers. T cell immunoglobulin and mucin domain 3 (TIM3) is an inhibitory …

T-cell immunoglobulin and mucin domain 3 (Tim-3) is a transmembrane protein that in both
mice and humans has been shown to possess various functions in a context-dependent …

Hepatocellular carcinoma (HCC) is one of the most common tumors in the world, and its
mortality is still on the rise. Limited treatments and low chemotherapy sensitivity of HCC …

Patients with malignant tumor treated with immunotherapy have received significant clinical
benefits over the years. Immune checkpoint blocking agents, such as anti-cytotoxic T …

IFN-γ plays a central role in antitumor immunity. T cell Ig and mucin domain (Tim-3) is
expressed on IFN-γ–producing Th1 cells; on interaction with its ligand, galectin-9, Th1 …

T cell immunoglobulin and mucin domain 3 (TIM-3) was originally found to be expressed on
the surface of Th1 cells, acting as a negative regulator and binding to the ligand galectin-9 to …

One of the most common tumors in the world is hepatocellular carcinoma (HCC), and its
mortality rates are still on the rise, so addressing it is considered an important challenge for …